Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Kluza, Jérome ^a   Jendoubi, Manel ^a   Ballot, Caroline ^a   Dammak, Abir ^a   Jonneaux, Aurélie ^a   Idziorek, Thierry ^b   Joha, Sami ^b   Dauphin, Véronique ^b   Malet Martino, Myriam ^c   Balayssac, Stéphane ^c   Maboudou, Patrice ^d   Briand, Gilbert ^d   Formstecher, Pierre ^a   Quesnel, Bruno ^b   Marchetti, Philippe ^a,d  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c UPS)   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; PYRUVIC ACID; ARSENIC TRIOXIDE; GLUCOSE; ISOTHIOCYANIC ACID DERIVATIVE; ORGANOARSENIC DERIVATIVE; OXIDE; PHENETHYL ISOTHIOCYANATE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CITRIC ACID CYCLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; ANIMAL; BIOLOGICAL MODEL; CELL DEATH; CELL RESPIRATION; DRUG EFFECT; DRUG RESISTANCE; ELECTRON TRANSPORT; ENERGY METABOLISM; LEUKEMIA; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ARSENICALS; CELL DEATH; CELL LINE, TUMOR; CELL RESPIRATION; DRUG RESISTANCE, NEOPLASM; ELECTRON TRANSPORT; ENERGY METABOLISM; GLUCOSE; ISOTHIOCYANATES; LEUKEMIA; MICE; MITOCHONDRIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; OXIDES; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

EID: 79960630736     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021924     Document Type: Article

References (44)

1. Walz C, Sattler M, (2006) Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57: 145-164.
2. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
4. Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, et al. (2006) Not all imatinib resistance in CML are BCR-ABL kinase domain mutations 1. Ann Hematol 85: 841-847.
5. Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, et al. (2005) Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24: 3257-3267.
6. Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, et al. (2001) Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276: 37747-37753.
7. Bentley J, Walker I, McIntosh E, Whetton AD, Owen-Lynch PJ, et al. (2001) Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model. Br J Haematol 112: 212-215.
8. Bentley J, Itchayanan D, Barnes K, McIntosh E, Tang X, et al. (2003) Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem 278: 39337-39348.
9. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
10. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ, (2004) Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10: 6661-6668.
11. Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, et al. (2009) Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer 100: 923-931.
12. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, et al. (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res 15: 3442-3450.
13. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, et al. (2005) Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105: 1717-1723.
14. Naughton R, Quiney C, Turner SD, Cotter TG, (2009) Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 23: 1432-1440.
15. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
16. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, et al. (2008) Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22: 1191-1199.
17. Vereecque R, Buffenoir G, Gonzalez R, Preudhomme C, Fenaux P, et al. (1999) A new murine aggressive leukemic model. Leuk Res 23: 415-416.
18. Liu J, Joha S, Idziorek T, Corm S, Hetuin D, et al. (2008) BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22: 791-799.
19. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
20. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, et al. (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 9809-9816.
21. Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, et al. (2007) Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc 2: 2295-2301.
22. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, et al. (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23: 7018-7030.
23. Castera L, Hatzfeld-Charbonnier AS, Ballot C, Charbonnel F, Dhuiege E, et al. (2009) Apoptosis-related mitochondrial dysfunction defines human monocyte-derived dendritic cells with impaired immuno-stimulatory capacities. J Cell Mol Med 13: 1321-1335.
24. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
25. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, et al. (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692-2703.
26. Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JM, et al. (2006) Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res 66: 3177-3187.
27. Ballot C, Kluza J, Lancel S, Martoriati A, Hassoun SM, et al. (2010) Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 15: 769-781.
28. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, et al. (1994) Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 228: 35-51.
29. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, et al. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621.
30. Moreadith RW, Lehninger AL, (1984) The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 259: 6215-6221.
31. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, et al. (2004) Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64: 985-993.
32. Michelakis ED, Webster L, Mackey JR, (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99: 989-994.
33. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, et al. (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275: 24273-24278.
34. Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, et al. (2009) Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 158: 588-600.
35. Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, et al. (2010) Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 29: 2962-2972.
36. Semenza GL, (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39: 231-234.
37. Warburg O, (1956) On respiratory impairment in cancer cells. Science 124: 269-270.
38. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
39. Kim JW, Tchernyshyov I, Semenza GL, Dang CV, (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
40. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14: 2231-2239.
41. Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, et al. (2006) Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia 20: 1731-1737.
42. Mason EF, Zhao Y, Goraksha-Hicks P, Coloff JL, Gannon H, et al. (2010) Aerobic Glycolysis Suppresses p53 Activity to Provide Selective Protection from Apoptosis upon Loss of Growth Signals or Inhibition of BCR-Abl. Cancer Res 70: 8066-8076.
43. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, et al. (2006) BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108: 319-327.
44. Trachootham D, Alexandre J, Huang P, (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.